For 105 patients with locoregional carcinoma of the prostate, prostate specific antigen (PSA) levels were evaluated before, during and after external beam radiotherapy. The median follow-up is 17 months. In 51 patients (48.5%) initial PSA levels exceeded the maximum normal value of 20 ng/ml. Nine patients kept non-declining high levels just after radiotherapy. Only one of these is free of disease. Assuming PSA levels decrease exponentially during radiotherapy, a mean half-life of 62 days (median 54, SD 26 days) was calculated. Three out of five patients with a PSA half-life of more than 88 days relapsed as compared to a 8% (3/37) relapse rate in patients with a "normal" half-life. Prolonged PSA half-life suggests residual disease. PSA levels are expected to further decrease after radiation. Six months after irradiation persistent high PSA levels were found in 14/51 (27.5%) patients. Only four of them had no evidence of manifest disease. Important negative prognostic factors for disease control in our series were non-declining high levels of PSA, a PSA serum half-life exceeding 88 days and persistence of elevated PSA values longer than six months after treatment. In our opinion, PSA is a valuable marker in the follow-up of prostate cancer patients during and after radiotherapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Type D personality and social inhibition: drivers of cardiovascular risk and reduced physical activity in psoriatic arthritis.
Clin Rheumatol
January 2025
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Cukurova University, Adana, Turkey.
Background: To evaluate the presence of type D personality and its association with metabolic syndrome (MetS), cardiovascular disease risk, and level of exercise in patients with psoriatic arthritis (PsA).
Material And Method: This cross-sectional study included patients with PsA (n = 84) and healthy controls (n = 74). Sociodemographic data, laboratory parameters, and disease-related parameters were recorded.
Label-free electrochemical immunoassay for ultra-sensitive detection of PSA utilizing gold nanoparticles/polyhedral hollow CoCu bimetallic sulfide nanostructure as a dual signal amplification platform.
Int J Biol Macromol
January 2025
Department of Analytical Chemistry, Faculty of Chemistry, Razi University, Kermanshah, Iran.
This study introduces the development of a highly sensitive label-free electrochemical immunosensor specifically designed to detect prostate-specific antigen (PSA). A glassy carbon electrode (GCE) coated with Au nanoparticles/polyhedral hollow CoCu bimetallic sulfide (CuCoS) was employed as a sensing interface for the fixation of the monoclonal anti-PSA antibody. The nanoarchitectures enhanced the capacity for loading prostate-specific antibodies (Ab) and effectually boosted electrical conductivity leading to enhance the electrochemical signal and greater sensitivity for the detection of PSA.
View Article and Find Full Text PDFMR-guided Transrectal Focal Laser Ablation for Localized Low- and Intermediate Risk Prostate Cancer: Initial Outcomes Using an Integrated Laser Ablation System.
J Vasc Interv Radiol
January 2025
Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands.
Purpose: To investigate the feasibility and safety of MRI-guided focal laser ablation (FLA) in localized, International Society of Urological Pathology (ISUP) grade 1-3, prostate cancer (PCa) using an integrated system.
Methods: Ten consecutive males (mean age: 66±7 years) with low-to-intermediate risk PCa were prospectively included (April 2022-May 2023) and treated with MRI-guided FLA using an integrated system for laser energy control and MR thermometry monitoring. Primary endpoints were technical success, procedure-related adverse events (AEs) following SIR (Society of Interventional Radiology) classification, and 12-months local tumor progression-free survival (LTPFS), defined as no evident residual/ recurrent disease on follow-up imaging or histopathology at the treatment site.
Incisional PSMA PET/CT-positive recurrences in prostate cancer- is there an implication on clinical care?
Clin Exp Metastasis
January 2025
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Oligorecurrent prostate cancer (PCa) can be treated with metastasis-directed therapy (MDT), which may be performed using radioguided surgery (RGS) as an experimental approach. These procedures have shown promising outcomes, largely due to the high lesion detection rate of positron emission tomography/computed tomography (PET/CT). We present a case series of patients who underwent RGS following robot-assisted radical prostatectomy (RARP).
View Article and Find Full Text PDFDigital tool as speech and language therapy for patients with post-stroke aphasia.
Digit Health
January 2025
Department of Neurology and Stroke Centre, Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital-Autonomous University of Madrid), Madrid, Spain.
Introduction: New technologies could play a role in post-stroke aphasia (PSA). Our aims were to develop a digital tool; to evaluate its acceptance and usability by patients and caregivers; and to demonstrate its effectiveness in improving language skills in patients with PSA, applying it from the acute phase.
Methods: The study consisted of two phases: development of a digital tool; and an interventional before-and-after study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!